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Facing the ongoing challenge of the febrile
young infant
Adrienne G. DePorre1,2*, Paul L. Aronson3 and Russell J. McCulloh1,2

Abstract
This article is one of ten reviews selected from the
Annual Update in Intensive Care and Emergency
Medicine 2017. Other selected articles can be found
online at http://ccforum.com/series/annualupdate2017.
Further information about the Annual Update in
Intensive Care and Emergency Medicine is available
from http://www.springer.com/series/8901.

Background
Fever in young infants (i. e., infants ≤ 90 days of life) is a
frequent complaint encountered by health care providers, and medical decision‐making regarding testing,
disposition, and treatment of the febrile infant can be
challenging. In the developed world, these otherwise
well‐appearing young infants are commonly evaluated by
clinicians in the ambulatory and emergency department
(ED) setting, and they pose a significant conundrum to
clinicians for a variety of reasons.
Fever is often the only sign of illness in young infants,
making it clinically difficult to differentiate infants with
a benign self‐limiting illness from those with a more serious illness that could progress to sepsis, permanent disability or death if left untreated. Because of this clinical
uncertainty, many febrile young infants undergo invasive
testing, are administered empiric antibiotics and are admitted to the hospital. Currently there is no consensus
regarding the optimal management and treatment strategy for the febrile young infant. While multiple criteria
have been developed to stratify infants based on their
risk for serious bacterial infections, the most commonly‐
used of these criteria are over 25 years old, and these
criteria do not account for the changing incidence and
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epidemiology of invasive infections in young infants or
for advances in medical technology for identifying bacteria and viruses responsible for severe infections. Finally, current treatment recommendations largely ignore
the potential negative consequences of over‐testing, including false‐positive test results, excessive antibiotic use
and the psychological and financial hardships to which
patients’ families may be subjected in the course of
evaluating these at‐risk infants.
In this chapter, we will highlight the historical context of
febrile infant management, review important definitions
and terminology, discuss the most clinically relevant viral
and bacterial causes of fever in the young infant, describe
current risk stratification tools guiding medical‐decision
making, and outline research and clinical practice improvement priorities for improving the management of
the febrile young infant.

Historical context
Since the mid‐1970s, there have been numerous published
recommendations for the suggested work‐up and treatment of nontoxic young febrile infants. These recommendations have changed through the years as medical
technology, antibiotic agents and maternal and neonatal
healthcare have advanced, and as emerging information is
shared. Many of the first recommendations were based on
prior reports of occult bacteremia in children, which most
often were caused by Streptococcus pneumoniae, Hamophilus influenzae type b, and Neisseria meningitidis, leading to invasive meningitis [1, 2]. Early reports focusing on
infants in the first 1–3 months of life identified Streptococcus agalactiae (hereafter referred to as Group B Streptococci [GBS]) and enterobacteraceae, especially Escherichia
coli and Salmonella spp., as common causes of bacteremia
and meningitis [3–5]. Due in part to these risks, in the
1970s and early 1980s it was generally recommended that
all febrile infants have blood, urine and cerebrospinal fluid
(CSF) cultures drawn, receive empiric antibiotics, and be
admitted to the hospital pending culture results, though
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the exact age limit for when this strategy should generally
be employed varied widely.
In the mid‐1980s, reflecting healthcare overutilization
and risks associated with previous recommendations,
risk‐stratification algorithms based on clinical and laboratory features were created that identified infants at
lower risk for serious bacterial infection who could safely
be monitored outside of the hospital and often without
antibiotics [6]. The most commonly used criteria in the
US that were developed during this time include the
Boston, Milwaukee, Philadelphia, and Rochester criteria.
These criteria, developed largely on single‐site experiences with evaluating febrile infants at tertiary medical
centers, were effective in identifying infants at relatively
low risk for bacterial meningitis and bacteremia (negative predictive value [NPV] 93–100%) [7–10]. These criteria form the basis for many local and professional
society recommendations and clinical practice guidelines
currently in use by healthcare providers [6, 11].
However, while these criteria demonstrate reasonably
high reliability for identifying infants at low risk for serious bacterial infection, there are increasing limitations.
First, these criteria were not designed to identify febrile
young infants at high‐risk for bacterial infection. Second,
none of the risk‐stratification systems reliably identified
low‐risk infants younger than 1 month of age. Additionally, none of the algorithms could account for subsequent technological advances for rapidly and reliably
diagnosing viral infection in young infants, which can
greatly affect the likelihood of an infant having a bacterial infection [12]. Given these limitations, it is unsurprising that contemporary practices in evaluating and
managing young febrile infants vary widely in both the
inpatient and outpatient settings [11, 13].

Definitions
Fever in young infants is defined as a rectally‐obtained
temperature ≥ 38 °C (100.4 F). Temperature taken by
touch, in the axilla or the ear is less accurate, although
studies have also shown that caregiver reports of fever
correlated with rectal thermometer measurement in up
to 79% of patients [14, 15]. Thus, it is recommended
that infants solely with caregiver report of fever be taken
as seriously as those with findings of fever at the clinical
visit.
Common terms used in discussions focused on febrile
young infants that warrant further definition include
‘serious bacterial infection’ and ‘invasive bacterial infection’. The term serious bacterial infection classically includes bacterial urinary tract infection (UTI), bacteremia
and bacterial meningitis. Occasionally, in cases where a
known bacterial pathogen is identified as the cause,
bacterial pneumonia, enteritis, skin and soft tissue

Page 2 of 8

infections and bone infections are included under the
term serious bacterial infection [16].
More recently, the phrase invasive bacterial infection
has been used to describe infants with bacterial meningitis
or bacteremia, reflecting the generally good outcomes of
infants diagnosed with UTI [17]. Some experts recommend the sole use of infection source (e. g., meningitis,
bacteremia, UTI, etc.) to promote clarity in nomenclature.

Epidemiology of infections in febrile infants
Viruses are thought to cause the majority of febrile illnesses in young infants, and identifying a viral infection
is often associated with a lower risk of bacterial infection
in these infants (Table 1). A comprehensive description
of the exact epidemiology and incidence of bacterial
causes of fever in the young infant is difficult. To date,
no large‐scale, multi‐site estimates of bacterial infection
prevalence have been conducted, with available reports
relying on data obtained primarily from single‐site surveys over varying time periods. High‐quality data on the
prevalence of bacterial infections in different age groups
is also lacking [1]. Overall, bacterial infections are identified in roughly 8–10% of febrile infants.
Viral infections

Herpes simplex virus (HSV) is a rare but significant cause
of morbidity and mortality among febrile infants, being
identified in < 0.3% of febrile infants, but with an associated mortality of > 15%, a risk that is increased with delay
in initiation of antiviral therapy [18, 19]. The majority of
neonatal HSV disease is transmitted to the newborn by
active maternal shedding of the virus during the peripartum period. Infection most commonly occurs in the first
month of life, and it is exceedingly rare in children older
than 6–8 weeks of age. HSV infection can be categorized
as limited to skin, eye, mouth (SEM disease); disseminated
disease/sepsis; or meningoencephalitis (which can complicate both sepsis and SEM disease), and can be caused by
either HSV‐1 or HSV‐2. Fever can be the only feature of
HSV infection, although it may be lacking in up to 50% of
infants ultimately diagnosed with HSV disease, and other
clinical symptoms, including vesicular rash, seizures, ill or
toxic appearance, irritability, lethargy, conjunctivitis, bulging fontanel and temperature instability, can aid in the
diagnosis [20]. These clinical symptoms, along with laboratory findings, such as elevated liver function tests and
CSF pleocytosis, are more commonly found in infants
with HSV than without, and the presence of any of these
signs and symptoms should prompt the consideration of
HSV testing and empiric treatment with acyclovir.
Enterovirus is one of the most common causes of
febrile illness in young infants and its incidence varies
seasonally, with rates being highest in the summer
and fall. During these times, enterovirus infection is
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Table 1 Common viral illnesses presenting as fever in young infants and association with bacterial illness. Data from
references [21, 24, 25, 45–48]
Virus

Recommended diagnostic test

Association with bacterial illness

Enterovirus (EV)

CSF EV PCR; EV serum PCR if EV sepsis is suspected

Low risk for concomitant bacterial meningitis and
bacteremia. Decreased risk for UTI

Human parechovirus (HPeV)

CSF HPeV PCR

Insufficient data, but likely decreased risk of bacterial
meningitis, bacteremia, and UTI

Respiratory syncytial virus (RSV)

Nasopharyngeal RSV Ag detection or RSV RT‐PCR

Low risk for concomitant bacterial meningitis or
bacteremia. Decreased risk for UTI

Influenza A/B

Nasopharyngeal Influenza A/B Ag detection or
Influenza A/B RT‐PCR

Low risk for concomitant bacterial infection

Human rhinovirus (hRV)

Nasopharyngeal rhinovirus PCR

Unknown. Due to prolonged viral shedding, unable
to solely attribute febrile illness to rhinovirus

Adenovirus (ADV)

Nasopharyngeal adenovirus RT‐PCR

Unknown. Due to prolonged viral shedding, unable
to solely attribute febrile illness to adenovirus

Human parainfluenza virus (HPIV) 1,2,3,4 Nasopharyngeal HPIV 1,2,3,4 RT‐PCR

Insufficient data, but likely low risk of concomitant
bacterial infection

Rotavirus (ROTA)

Insufficient data, but likely low risk of concomitant
bacterial infection

Stool rotavirus Ag detection, stool rotavirus enzyme
immunoassay or rotavirus PCR

Herpes simplex virus (HSV) Types 1 and 2 CSF HSV PCR, viral culture or PCR of vesicles
Surface cultures in neonates (mouth, nasopharynx,
conjunctivae, perianal)
Serum HSV PCR (if available)

Insufficient data, but likely low risk of concomitant
bacterial infection

Human herpes virus‐6 (HHV‐6)

Insufficient data, but likely low risk of concomitant
bacterial infection

Plasma HHV‐6 RT‐PCR; HHV‐6 serologic antibody
titers

PCR polymerase chain reaction, RT‐PCR reverse‐transcriptase polymerase chain reaction, CSF cerebrospinal fluid, UTI urinary tract infection

found in 40–50% of admitted febrile infants [21]. Because enterovirus‐positive infants have a low rate of
concomitant bacterial infections, management of enterovirus‐positive infants often consists of supportive
care alone. A rare manifestation of enterovirus infection in neonates includes severe viral sepsis, which is
generally associated with maternal acute infection
with enterovirus near the time of delivery. Treatment
for enterovirus sepsis is also limited to supportive
care with the possible addition of intravenous immune globulin, as no FDA‐approved or compassionate‐use antiviral therapy is currently available. Testing
for enterovirus is encouraged, especially during summer and fall seasons, as a confirmed diagnosis allows
clinicians to safely decrease hospital length of stay
and antibiotic exposure for otherwise well‐appearing
febrile infants [22].
Human Parechovirus (HPeV) is a relatively recently described cause of viral meningitis and encephalitis among
febrile infants. Similar to enterovirus, HPeV is a picornavirus with seasonal variation, and treatment consists
largely of supportive care. Compared to enterovirus‐positive infants, HPeV‐positive infants typically appear more
acutely ill and more often require ICU care [23]. While
the rates of concomitant bacterial infections are thought
to be low (similar to those of enterovirus), suggesting that
HPeV‐infants could be monitored off antibiotics, further
data are needed to confirm this [23].

Respiratory viruses, particularly respiratory syncytial
virus (RSV), influenza viruses A and B, rotavirus, and
rhinovirus are also commonly identified in the febrile infant (Table 1). With the exception of rotavirus, these viruses often cause respiratory symptoms, most commonly
manifested as bronchiolitis. Because well‐appearing febrile
RSV‐positive infants are at low risk for bacterial meningitis and bacteremia, but still have a notable risk for bacterial UTI [24], management and testing of these infants
should include urinalysis and urine culture, and in most
well‐appearing infants without evidence of UTI, antibiotics and routine lumbar punctures can be safely delayed
or avoided. Similarly, the risk of bacterial infection among
infants with influenza or rotavirus is low [25]. The detection of rhinovirus in the otherwise well‐appearing febrile
infant does not necessarily decrease an infant’s risk for
concomitant bacterial infection because, due to its long
shedding period, detection of the virus may not correlate
with acute viral illness [26].
Other viruses and their potential association with the
risk of bacterial infection in febrile young infants are detailed in Table 1.
Bacterial infections

A description of the exact epidemiology and incidence
of bacterial causes of fever in the young infant is difficult, as recent large datasets are lacking. However, meta‐
analyses and data from single‐center or regional data in
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the United States suggest that while the majority of bacterial infections used to be due to GBS, and Listeria was
of relatively greater concern, E. coli and other Gram‐
negative bacteria now account for the majority of infections, and Listeria monocytogenes is a rarely encountered
pathogen [27, 28].
In addition to E. coli, other Gram‐negative infections of
importance include Klebsiella pneumoniae, Citrobacter
spp., Enterobacter spp., Salmonella spp. and Serratia marcescens. About 20% of serious bacterial infections are
thought to be due to Gram‐positive bacteria [15]. The
most commonly‐isolated Gram‐positive organisms include
GBS, Staphylococcus aureus and Enterococcus spp. L.
monocytogenes is now considered an extremely rare cause
of serious bacterial infection in the United States [27–29].
UTIs are the most common cause of serious bacterial
infection, with E. coli causing the majority of infections. It
is thought that UTIs occur in roughly 9% of all febrile infants who undergo medical evaluation, making up roughly
85% of all serious bacterial infection in this population
[16, 24]. Despite the relatively high incidence of UTI
among febrile infants, consensus regarding the disposition
and treatment duration of febrile young infants with UTI
is lacking. The perceived risk of developing concomitant
bacteremia or meningitis and/or long‐standing renal injury drives common practice, which frequently includes
hospital admission, invasive CSF testing, and often a 2‐
week course of parenteral antibiotics.
It is now questioned whether these infants should be
treated less conservatively, as the risk of bacterial meningitis, shock, or death is thought to be extremely low in
otherwise well‐appearing infants [17]. While the risk of
bacteremia secondary to UTI remains substantial, it is

unlikely to be associated with adverse effects, and recent
studies on well‐appearing infants with bacteremia secondary to UTI show similar clinical outcomes between
those treated with a prolonged course of parenteral antibiotics vs. those treated with shorter courses of parenteral antibiotics [17, 30, 31].
Bacteremia and bacterial meningitis in febrile infants
are thought to occur at an incidence of roughly 1.8–2%
and 0.5–0.7%, respectively [13, 24]. Unlike UTI, bacterial
meningitis is associated with a 5% mortality risk and
long‐term sequelae, such as hearing loss, seizures, motor
problems, hydrocephalus, and cognitive and behavioral
problems, underscoring the need for early detection and
treatment of bacteremia (which may lead to bacterial
meningitis) and bacterial meningitis [32].

Tools for risk stratification
A combination of age, clinical appearance and laboratory
values is commonly used to identify young febrile infants
at risk for a serious bacterial or viral infection.
The Rochester, Philadelphia, Milwaukee and Boston criteria all use the above combination to identify infants at
low risk for serious bacterial infection. While the laboratory tests used, interpretation of test results, empirical
antibiotic use, and age at which criteria should be applied,
vary across these tools, there are many similarities among
them (Table 2). Regardless of laboratory values, febrile infants who are ill‐appearing or < 28 days old are identified
as at higher risk for serious bacterial infection. It is generally recommended that young febrile infants be evaluated
with a complete blood count with differential, urinalysis,
blood, and urine culture. Blood and urine tests are often

Table 2 Clinical and laboratory findings of common low‐risk criteria. Adapted from [12]
Boston

Milwaukee

Philadelphia

Rochester

Age range

28–89 days

28–56 days

29–60 days

≤60 days

History

No immunizations or
antimicrobials in prior
48 h

Not defined

Not defined

Term infant; no prior antibiotics; no
underlying disease; no
hospitalization longer than mother

Physical exam

Well appearing; no
signs of focal infection

Well appearing; no signs of focal
infection

Well appearing; no signs Well appearing; no signs of focal
of focal infection
infection

Laboratory
parameters

CSF < 10 WBC/mm3
WBC < 20,000 mm3
UA < 10 WBC/hpf
CXR without infiltrate
(if obtained)

CSF < 10/mm3
WBC < 15,000/mm3
UA < 5–10 WBC/hpf; UA no bacteria,
negative leukocyte esterase, negative
nitrites
CXR without infiltrate

CSF < 8 WBC/mm3
WBC < 15,000/mm3
UA < 10 WBC/hpf
CXR without infiltrate
(if obtained)

WBC > 5000 and < 15,000/mm3
ABC < 1500/mm3
UA ≤ 10 WBC/hpf
CXR without infiltrate (if obtained)
Stool: WBC ≤ 5/hpf smear
(if indicated)

Management
strategies for
high risk

Hospitalize, empiric
antibiotics

Not defined

Hospitalize, empiric
antibiotics

Hospitalize, empiric antibiotics

Management
strategy for low
risk

Home/outpatient ok
Empiric antibiotics,
outpatient follow up
required

Home/outpatient ok
i.m. ceftriaxone 50 mg/kg followed by
outpatient follow up within 24 h
Must have reliable caretaker

Home/outpatient ok
No antibiotics, but
outpatient follow up is
required

Home/outpatient ok
No antibiotics, but outpatient follow
up is required

CXR chest X‐ray, UA urinalysis, CSF cerebrospinal fluid, WBC white blood cells, ABC absolute band count, hpf high power field, i.m. intramuscular
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obtained simultaneously, and obtaining CSF depends on
which strategy is used. Chest radiographs are not routinely
recommended.
Although useful in predicting illness severity in older
infants and children, the Yale Observational Score, a
scoring system that uses clinical signs and symptoms to
determine the risk of serious bacterial or viral illness, is
not an accurate risk‐stratification tool among young febrile infants < 8 weeks of age [33].
A sequential approach for identifying febrile young infants at low risk for invasive bacterial infection has been
proposed. Highlighting UTI as the most common bacterial infection in young febrile infants, this approach recommends evaluating age, clinical appearance and urinalysis
results prior to obtaining blood samples [34]. This step‐
by‐step approach has been prospectively validated and has
a high sensitivity (92%) and NPV (99.3%) [35].
There has been much debate about the utility of certain biomechanical markers as part of a febrile infant
evaluation. While an abnormal white blood cell (WBC)
count in a febrile young infant is associated with serious
bacterial infection, it is not a specific marker for serious
bacterial infection (positive predictive value of 30–43.8%
for WBC < 5,000 or > 15,000/mm3) [12].
Compared to an abnormal WBC, elevated C‐reactive
protein (CRP) and procalcitonin (PCT) values are associated with serious bacterial infection with a greater sensitivity and specificity, with PCT being more sensitive
than CRP for diagnosis of invasive bacterial infection
[34, 36]. CRP can often be elevated in viral infections
and does not rise as acutely as PCT levels do, which can
cause both false positive and negative results, respectively. While PCT use has been widely investigated in the
adult sepsis literature, its use in febrile young infants has
been mostly limited to European studies. Using PCT is
limited in many non‐European countries, as it is not
widely available, is not rapidly performed and is associated with high laboratory costs [34, 36]. Combining
PCT, CRP and presence of leukocyte esterase or nitrites
on urinalysis into a single “lab score” has better specificity to predict the presence of serious bacterial infection
than do WBC, CRP or PCT alone, but has a low sensitivity [37]. New research has also identified that an
infant produces a unique host response, called an
RNA‐biosignature, secondary to bacterial infection, which
can be detected by microarray analysis. Data on the role
of RNA‐biosignatures in the management of the febrile
young infant are emerging and future studies are needed
to evaluate their utility in the clinical setting [38].
Emerging evidence on 1) the changing epidemiology and
incidence of bacterial infections; 2) patient outcomes with
certain bacterial infections, such as UTIs; 3) the low risk of
concomitant bacterial infections among infants with viral
illnesses; 4) risk of serious illness with viral illnesses such as
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enterovirus and HSV; and 5) the need for judicious testing
that limits the negative consequences of febrile infant evaluations is reshaping how infants are risk‐stratified.
Many health care centers and institutions have created
site‐specific practice guidelines for the management of
the febrile young infant, some of which advocate for
more judicious testing and risk‐stratify febrile infants
based on viral status. These guidelines have been associated with good outcomes, including decreased hospital
costs, hospital lengths of stay, and antibiotic exposure
without any increase in adverse events [39]. However,
guidelines vary widely across institutions, and not all
guidelines advocate for more judicious testing and antibiotic use, which can affect health care costs and contributes to the observed variation in practice [11].

Therapeutic options
For those infants at low risk of serious infection, outpatient management with close monitoring and primary
care follow‐up is recommended. Antibiotic administration is dependent on which strategy is used, but, in general, antimicrobials should not be given to well‐
appearing febrile infants until after blood, urine and CSF
cultures are obtained.
High‐risk infants require hospitalization for empiric
intravenous antimicrobials pending bacterial and viral
testing results. Hospital length of stay depends on culture and viral testing results. While many clinicians observe infants on empiric antibiotics until all bacterial
cultures are negative for 36–48 h, this practice varies
widely and is rapidly changing. New evidence has suggested that, due to advances in automated culture detection, an observation period pending negative bacterial
culture results at 24–36 h is often appropriate and can
reduce antibiotic exposure, hospital length of stay, and
healthcare costs without an increase in missed bacterial
infections [39, 40]. In addition, due to the low risk of
concomitant bacterial infections, in otherwise well‐
appearing enterovirus‐positive infants, short observation
periods of no more than 24 h are generally recommended [39]. Other potential adjustments to management based on virological test results and PCT results
are detailed in Table 3. Hospital admission can often
come at a time when infant‐family bonding is just beginning, and therefore should focus on maximizing family
bonding by encouraging breast feeding, skin‐to‐skin contact, and maintaining previous routines, while minimizing unnecessary tests and interventions.
Empiric antibiotic choices should cross the blood
brain barrier and target the most common pathogens,
such as E. coli and GBS. In a large regional study, almost 80% of infants with meningitis were infected
with ampicillin‐resistant organisms, highlighting the
need for identification of and treatment according to
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Table 3 Diagnostic tests and their utility in the well‐appearing febrile young infant. Data from references [22, 25, 49, 50]
Test

Indications

Potential role in management

RSV testing

Infants with respiratory symptoms

If positive, may safely avoid LPs, antibiotic
exposure, and hospitalizations

EV testing

Infants undergoing LP and CSF studies

If positive, may consider discontinuing antibiotics,
discharge home if bacterial cultures negative at
24–36 h

Influenza testing

Infants with respiratory symptoms, especially
during high regional prevalence

If positive, may consider discontinuing antibiotics,
discharge home if bacterial cultures negative at
24–36 h

Procalcitonin

Otherwise low‐risk infants with negative
virological testing

If normal/minimal elevation: may consider initial
inpatient observation off antibiotics, avoidance of
LP, or outpatient management

LP lumbar puncture, CSF cerebrospinal fluid, RSV respiratory syncytial virus, EV enterovirus

regional and institution‐specific antibiotic resistance
patterns [16]. Medication side‐effects are also a factor
when determining appropriate antibiotic choices. For
example, in infants < 28 days old who are already at
increased risk for kernicterus, ceftriaxone is generally
avoided as it can cause further increases in serum
bilirubin levels.
Commonly‐used antibiotic regimens for infants < 28 days
old include ampicillin and either an aminoglycoside, such
as gentamicin, or a third‐generation cephalosporin, such
as cefotaxime. For infants > 28 days of age, a third‐generation cephalosporin, such as ceftriaxone, is often used as
monotherapy. For those infants at risk of HSV infection,
acyclovir should be empirically administered pending
HSV test results.

Unintended consequences of testing/treatment
The risk of delayed care of a febrile young infant with a
serious infection drives invasive testing, hospitalization
and antibiotic use, but in some cases these interventions
are unnecessary and can often have unintended negative
consequences, such as vulnerable child syndrome, family
stress, prolonged hospital stay, increased hospital costs,
and iatrogenic complications.
Vulnerable child syndrome is a well‐described syndrome
in which a caregiver’s perception of their child as being
vulnerable leads to a dysfunctional parent‐child relationship. Clinical features of vulnerable child syndrome in the
caregiver include excessive separation anxiety, over‐protective behavior, difficulties with discipline, and excessive
use of the medical system; children can display impaired
sleeping habits, difficulties in school, exaggerated separation anxiety, and hypochondria [41, 42]. Children hospitalized early in life, such as those born premature, those
with congenital malformations, or those with a suspected
serious illness (which one could argue includes suspected
meningitis) have been shown to be more prone to vulnerable child syndrome [42].
Parents of hospitalized infants who were interviewed
in an effort to better characterize the stress and

difficulties families of febrile infants face have previously
described believing that their infant had a weak immune
system and could rapidly deteriorate or die. Parents have
also reported feeling an overwhelming sense of responsibility, a lack of control, experiencing disruption of
breast‐feeding and increased financial stress [43].
Potentially unnecessary or avoidable testing of febrile
infants can cause negative consequences by prolonging
hospitalizations and increasing healthcare‐related costs.
Due to the development of a reliable rapid HSV polymerase chain reaction (PCR) test, many infants at low
risk of HSV infection (i. e., well‐appearing infants without any historical risks, signs, or symptoms of HSV) are
tested and given empiric acyclovir pending PCR results.
This testing and empiric treatment of all febrile infants
may increase hospital length of stay, and healthcare
costs without conferring any additional benefits [44].
Iatrogenic harm caused by the management and treatment of febrile infants has not been well studied. Common
sources of iatrogenic harm likely include antimicrobial pre‐
treated CSF cultures and traumatic lumbar punctures [45],
which may cause unnecessary antibiotic exposure; radiation
exposure from x‐rays or other imaging; and phlebitis or
venous injury during blood draws or infusions. Due to the
relatively low incidence of bacterial infections among febrile
infants, bacterial cultures have a low positive predictive
value, and can often result in false‐positive culture results.
False‐positive test results likely lead to even further caregiver stress, invasive testing, antibiotic exposure, hospital
days and healthcare costs.

Conclusion/future priorities
Caring for the febrile young infant is often challenging,
as the fear of not properly treating a serious illness can
often lead to unnecessary testing, antibiotics and
hospitalization. To better guide management descisions,
future research priorities should focus on using large
multi‐regional data to identify the incidence and epidemiology of bacterial infections, and further attempts
should be made to identify infants at high‐risk of
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invasive bacterial and HSV infection. Viral testing should
be incorporated into febrile infant evaluations, as identification of a virus may decrease antibiotic exposure, invasive testing and hospitalization. Continued efforts
should be made towards the study of novel diagnostic
tools such as RNA biosignatures. Finally, there is a large
gap in our understanding of the consquences of current
febrile infant managment methods, and future efforts
should focus on better delineating the risks and unintended consequences of testing, antibiotic administration
and hospilization of young febrile infants.
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